LCS
ESPR

Levin Capital Strategies’s Esperion Therapeutics ESPR Stock Holding History

Levin Capital Strategies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-72,133
Closed -$1.02M – 315
2013
Q2 		$1.02M Buy
+72,133
New +$1.02M 0.02% 214

Other funds holding ESPR

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return

Levin Capital Strategies's ESPR Position: Q3 2013 in Review

Levin Capital Strategies sold out of Esperion Therapeutics (ESPR) in Q3 2013, closing a stake of 72,133 shares — an estimated $1.02M sold.

Levin Capital Strategies first reported a position in ESPR in Q2 2013 and held it in 1 quarter. The position peaked at $1.02M in Q2 2013. 44 funds tracked by Wall St. Rank hold ESPR as of Q3 2013.

  • Levin Capital Strategies reported no remaining Esperion Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Levin Capital Strategies sold 72,133 Esperion Therapeutics shares in Q3 2013, an estimated $1.02M.
  • Levin Capital Strategies first reported a position in Esperion Therapeutics in Q2 2013 and held it in 1 quarter.
  • Levin Capital Strategies's Esperion Therapeutics position peaked at $1.02M in Q2 2013.
  • 44 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2013.

Based on Levin Capital Strategies's 13F filing for Q3 2013, filed 12 Nov 2013.